(Re)configuring research value: international commercial clinical trials in the Russian Federation
Clinical trials of new drugs are generally understood in terms of contribution to the future well-being of patients and society at large, while studies of the political economy of trials reveal that global health inequalities have come to sustain the continuous and lucrative operation of this enterprise. The divide between profit generation and improvements in local well-being could be especially vivid when international commercial clinical trials are conducted in new, non-traditional locations outside of North America and Western Europe. This article focuses on how this divide is managed in the everyday work of conducting trials in a research centre in Russia. It explores how investigators and research participants engage in the work of translating trials into academic capacity-building, development of local medical expertise and provision of public health benefits. That is, research value is being multiply configured in clinical, scientific and economic domains. We view the conduct of clinical trials as a boundary process which, through enabling multiplication of value, bridges the realms of health and wealth. This reading of the process of conducting trials opens up opportunities to think about ways to maximise the value of medical experimentation and to (re)link clinical research and public good.
Keywordsclinical trials Russia health inequalities boundary process cardiovascular disease
This article benefited from perspectives of many physicians-investigators and clinical research experts in Russia. Authors are especially grateful to Dr Grant Shekhyan and Svetlana Zavidova. The authors appreciate careful proofreading of the text by Jean Kollantai.
Authors declare no conflict of interest.
- ACTO (Association of Clinical Trials Organisations) (2015) ACTO Newsletter #10: Summary of 2014 results. Moscow. http://acto-russia.org/files/ACTO_Newsletter_10.pdf, accessed 30 September 2015.
- Anokina, A. and Meshkov, D. (2007) Going further east in CEE. International Clinical Trials (Summer): 24–29.Google Scholar
- Babayan, E.A. and Ytkin, O.B. (1982) General principles of assessment of medicines in USSR and other countries/Бабаян Э.А. и Уткин О.Б. (1982) Основные положения апробации лекарственных средств в СССР и зарубежных странах. М: Медицина.Google Scholar
- Belmont Report (1979) The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research, hhs.gov/ohrp/humansubjects/guidance/belmont.html.
- Benatar, S.R. and Fleisher, T.E. (2007) Ethical issues in research in low-income countries. International Journal of Tuberculosis & Lung Disease 11(6): 617–623.Google Scholar
- Clarke, A.E. and Star, S.L. (2008) The social worlds framework: A theory/methods package. In: E.J. Hackett, O. Amsterdamska, M. Lynch and J. Wajcman (eds.) The Handbook of Science and Technology Studies. Cambridge, MA: MIT Press, pp. 113–139.Google Scholar
- Cooper, M. (2008) Experimental labour – offshoring clinical trials to China. East Asian Science, Technology and Society: An International Journal 2(1): 73–92.Google Scholar
- de Vries, M.C. et al (2011) Ethical issues at the interface of clinical care and research practice in pediatric oncology: A narrative review of parents’ and physicians' experiences. BMC medical ethics 12(18), www.biomedcentral.com/1472-6939/12/18.
- Epstein, S. (1996) Impure Science: AIDS, Activism and the Politics of Knowledge. Berkeley, CA: University of California Press.Google Scholar
- Fisher, J.A. (2009) Medical Research for Hire: The Political Economy of Pharmaceutical Clinical Trials. New Brunswick, NJ: Rutgers University Press.Google Scholar
- Fisher, J.A. (2015) “Ready-to-recruit” or “ready-to-consent” populations? Informed consent and the limits of subject autonomy. In: S. Sismondo and J.A. Green (eds.) The Pharmaceutical Studies Reader. Wiley-Blackwell, pp. 195–207.Google Scholar
- Fujimura, J.H. (1992) Crafting science: Standardized packages, boundary objects, and “translation”. In: A. Pickering (ed.) Science as Practice and Culture. Chicago, IL: University of Chicago Press, pp. 168–211.Google Scholar
- Heaven, B. (2010) Bridging the ontological divide: Different social worlds in the conduct of a pilot study. In: T. Moreira and C. Will (eds.) Medical Proofs, Social Experiments: Clinical Trials in Shifting Contexts. Farnham: Ashgate Publishing, pp. 39–47.Google Scholar
- Kelly, A.H. and Geissler, P.W. (eds.) (2012) Investigating the ethics and economics of medical experimentation. In: The Value of Transnational Medical Research: Labour, Participation and Care. London: Routledge, pp. 1–12.Google Scholar
- Law, J. (2006) Big Pharma: How the World’s Biggest Drug Companies Control Illness. London: Constable & Robinson Ltd.Google Scholar
- Markina, N. (2013) In case electronic registration does not work, complain to the Ministry of Health/Маркина, Н. (2013) Если не работает электронная запись, жалуйтесь в Минздрав. Газета.ru. http://www.gazeta.ru/health/2013/07/12_a_5425073.shtml.
- Petryna, A. (2015) Clinical trials offshored: On private sector science and public health. In: S. Sismondo and J.A. Green (eds.) The Pharmaceutical Studies Reader. West Sussex: Wiley-Blackwell, pp. 208–221.Google Scholar
- Pharmvestnik (2013) Vladimir Gurdus: There are conditions for innovation development in Russia. May 28.Google Scholar
- Stefanov, I. (2007) Clinical trials come to Russia. International Clinical Trials (Fall): 43–50.Google Scholar
- Stefanov, I. (2008) Russian revolution. European Pharmaceutical Contractor (Spring): 14–18.Google Scholar
- Stefanov, I. and Tverdokhleb, P. (2008) Russia grows its CRO market. Applied Clinical Trials, 1 April.Google Scholar
- Zingerman, B. (2013) Electronic medical record and principles of its organisation. IT in Health Care/Зингерман, Б. (2013) Электронная медицинская карта и принципы ее организации. ИТ в здравоохранении. http://www.osp.ru/medit/blogs/bz/bz_109.html, accessed 1 February 2014.